– USA, CA – Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced the appointment of Nancy Thornberry to its Board of Directors, effective January 8, 2021.
“I’m excited to welcome Nancy to the Board,” said CEO, Dr. Ryan Watts. “Nancy’s industry experience spans all stages of pharmaceutical development from the discovery of new molecular entities to clinical research leading to the approval of important new classes of medicines. Her perspective will be an asset as we continue to advance a broad portfolio of therapeutic candidates to treat neurodegeneration.”
Ms. Thornberry’s extensive biotech leadership and pharmaceutical experience includes more than 30 years of development and discovery work in multiple disease areas, including diabetes and endocrinology.
About Nancy Thornberry
Ms. Thornberry is CEO of Kallyope. She was formerly SVP and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc. In this role, she led discovery and clinical research in diabetes, osteoporosis, fertility, and contraception. Before her role as Franchise Head, she initiated and was a leader of Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes. Among other notable scientific accomplishments is the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1).
For her scientific contributions, Ms. Thornberry has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award by the American Chemical Society, and in 2011 received the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind.
“It’s an honor to join Denali’s Board of Directors,” said Ms. Thornberry. “With a singular focus on neurodegeneration, Denali is tackling one of the biggest medical challenges that our society faces today. I am impressed with the breadth of Denali’s pipeline and the vast opportunities afforded by its platform technology for delivering biotherapeutics to the brain. I look forward to applying my insights as a drug developer towards Denali’s continued growth and success.”
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.
For information, visit www.denalitherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.